Klinik I für Innere Medizin, Universität zu Köln, Cologne, Germany.
Center of Excellence for Cellular Stress Responses in Aging-Associated Diseases, Köln, Germany.
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.
2008 年发布的国际慢性淋巴细胞白血病工作组(iwCLL)共识指南的上一版已被治疗 CLL 患者的医生和研究人员广泛接受。最近的进展包括疾病基因组图谱的发现、具有预后相关性的基因检测的发展以及微小残留疾病(MRD)的检测,再加上新型靶向药物的疗效令人印象深刻,这促使国际专家组提供更新的基于证据和专家意见的建议。这些建议包括修订版的 iwCLL 反应标准,更新 MRD 状态在临床评估中的应用,以及关于在管理 CLL 期间评估和预防病毒疾病的建议。